media – Page 142 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

the equity transfer contract has come into effect

On February 4, Chongqing Pharmaceutical Holdings (000950) issued an announcement on the progress of the proposed change in the equity structure of the controlling shareholder. The company disclosed a relevant indicative announcement on January 11, 2025. Chongqing Chemical and Pharmaceutical Holdings (Group) Co., Ltd., a shareholder of the controlling shareholder Chongqing Pharmaceutical and Health Industry Co., Ltd., and Chongqing Yufu Holdings Group Co., Ltd. signed an equity transfer contract, intending to transfer 49% of Chongqing Chemical and Pharmaceutical Holdings to Chongqing Yufu. It is worth noting that the actual controllers of Chongqing Chemical and Pharmaceutical Group and Chongqing Yufu are both the Chongqing State-owned Assets Supervision and Administration Commission. According to the announcement, as of January 27, 2025, the company has received the “Notice Letter” from Chongqing Medical Health, confirming that Chongqing Chemical and Pharmaceutical Group has obtained the approval of the Chongqing State-owned Assets Supervision and Administration Commission, and ...
- Source: drugdu
- 402
- February 5, 2025
Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%

Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%. Galaxy Securities said that the pharmaceutical sector has undergone a long period of adjustment, the overall valuation is at a low level, and the public offering positions are underweight. In 2025, under the policy background of supporting and guiding the development of commercial insurance, the payment side is expected to improve marginally, and innovative drugs and equipment are expected to benefit. The pharmaceutical market will usher in a recovery, and structural opportunities still exist. From the perspective of short-term and medium- and long-term deterministic growth, targets are selected, and innovative drugs and industrial chains are optimistic about the continued good performance this year. Investors without stock accounts can seize investment opportunities in innovative drugs through the link fund (014118) of the innovative drug Shanghai-Shenzhen-Hong Kong ETF. Source: https://finance.eastmoney.com/
- Source: drugdu
- 306
- February 5, 2025
Diet pills should be used with caution

Recently, oral semaglutide tablets were approved by the National Medical Products Administration for full marketing in China. This is the first and only oral GLP-1 (glucagon-like peptide-1) drug approved for marketing in China. The reporter learned in the interview that the number of patients who went to the hospital to consult about this oral semaglutide has increased recently, and some of them hope to lose weight with this drug. So what exactly is semaglutide tablets used to treat, and what is its relationship with the weight loss “magic drug” that has been frequently mentioned on social media before? Semaglutide is a class of GLP-1 receptor agonists. Its working principle is to stimulate insulin synthesis and secretion in a glucose concentration-dependent manner after binding to the GLP-1 receptor, and reduce the secretion of glucagon. At the same time, it can also act on the GLP-1 receptors of the central nervous system, ...
- Source: drugdu
- 261
- February 5, 2025
Losses of 900 million to 1.3 billion yuan are expected in 2024

Hainan Haiyao (000566) disclosed its 2024 performance forecast on the evening of January 27, and it is expected to achieve operating income of 1 billion to 1.2 billion yuan in 2024; net profit attributable to the parent company will be a loss of 900 million to 1.3 billion yuan, compared with a loss of 106 million yuan in the same period last year; net profit excluding non-recurring items will be a loss of 700 million to 1 billion yuan, compared with a loss of 410 million yuan in the same period last year; basic earnings per share will be -0.6937 yuan/share to -1.002 yuan/share. Based on the closing price on January 27, Hainan Haiyao’s current price-to-earnings ratio (TTM) is about -4.29 times to -6.2 times, price-to-book ratio (LF) is about 3.16 times, and price-to-sales ratio (TTM) is about 5.07 times. According to the data, the company’s main business is the ...
- Source: drugdu
- 269
- February 5, 2025
Shandong YaoBo’s controlling shareholder released the pledge of 8.48 million shares

On January 27, Shandong YaoBo (600529) issued an announcement that the controlling shareholder Shandong Luzhong Investment released the pledge of 8.48 million shares, accounting for 6.55% of its shares and 1.28% of the company’s total share capital; as of the date of the announcement, Luzhong Investment had pledged a total of 53.8 million shares, accounting for 41.58% of its shares and 8.11% of the company’s total share capital. In the first three quarters of 2024, Shandong YaoBo achieved revenue of 3.825 billion yuan and net profit attributable to the parent of 720 million yuan. Source: https://finance.eastmoney.com/
- Source: drugdu
- 304
- February 5, 2025
Popular weight loss drugs have benefits and risks

In an observational study published in the latest issue of Nature Medicine, scientists analyzed the health effects of using glucagon-like peptide 1 receptor agonists (GLP-1RAs), concluding that 42 health risks decreased and 19 health risks increased. GLP-1RAs have become popular in the past few years because of their claims of weight loss. People are also studying the broader efficacy of GLP-1RAs, including the treatment of diseases such as Alzheimer’s disease, osteoarthritis and sleep apnea. However, some adverse events such as suicidal tendencies and gastrointestinal problems have also been reported. Therefore, it is necessary to further study the health benefits and risks of GLP-1RAs. A team from Washington University in St. Louis analyzed data from the U.S. Department of Veterans Affairs and studied the relationship between the use of GLP-1RAs and 175 health outcomes in 215,970 diabetic patients. Compared with a control group using non-GLP-1RA anti-hyperglycemic drugs, participants using GLP-1RA had ...
- Source: drugdu
- 293
- February 5, 2025
2025 will be a year of overseas expansion | Make a wish in spring

In mid-January 2025, WuXi Biologics announced that the company will add 151 projects in 2024, bringing the total number of projects to 817; the company expects that 24 PPQ (process performance confirmation) projects will be advanced in 2025, and the Irish production facility is expected to achieve profitability as planned in 2025. The above announcement actually conveys two very important messages. In 2024, the number of new projects of WuXi Biologics reached a new high. At the same time, the company’s “pioneer” Irish base in the international layout of that year ushered in a major breakthrough. But behind this announcement, as WuXi Biologics CEO Chen Zhisheng commented, it was a year of “roller coaster” for WuXi Biologics. In the ten years from 2014 to 2023, WuXi Biologics’ revenue compound annual growth rate exceeded 50%, which means that the company achieved a growth rate that was three times higher than the ...
- Source: drugdu
- 449
- February 5, 2025
Tianyu shares Avatrombopag maleate API passed CDE review

On January 27, Tianyu shares (300702) issued an announcement that the company’s Avatrombopag maleate API recently passed the review of the National Drug Administration Drug Review Center (CDE). The API belongs to Class 4 chemical drugs, with a registration number of Y20230000333, and the review result and the preparation are jointly reviewed as A. The company submitted a registration application for Avatrombopag maleate API to CDE in June 2023 and was accepted. Although the API has passed the CDE review, it still needs to obtain the “compliance” result of the GMP compliance inspection of the Zhejiang Provincial Drug Administration before it can be marketed in China. At present, there are 14 manufacturers in China that have passed the CDE technical review. The company is preparing to apply for a GMP compliance inspection. There is still uncertainty about the time of listing and sales. Investors are reminded to make prudent decisions ...
- Source: drugdu
- 252
- February 5, 2025
From being crowded to being deserted, why has the business of consistency evaluation of generic drugs “cooled down”?

Recently, discussions about generic drugs and original research drugs have been heated, and the appearance of identical data in consistency evaluation has become the first “oolong” in the pharmaceutical industry in 2025. However, in the public opinion field, the voices of pharmaceutical companies and CRO (pharmaceutical research and development outsourcing) companies are almost inaudible. Even a CRO company told the reporter of “Daily Economic News” that “there has been no generic drug (consistency) test in the past five or six years.” This was hard to imagine eight years ago. In March 2016, the “Opinions of the General Office of the State Council on Conducting Consistency Evaluation of Generic Drug Quality and Efficacy” kicked off the domestic consistency evaluation of generic drugs. Pharmaceutical companies are willing to spend millions of yuan on consistency evaluation, and CRO companies are also very busy. The business of consistency evaluation of generic drugs by CRO ...
- Source: drugdu
- 277
- February 5, 2025
PD-(L)1 “rolls” into the second half and new drugs are launched. What is Kelun Botai selling?

On January 20, Kelun Pharmaceutical (SZ002422, stock price 28.13 yuan, market value 45.05 billion yuan) announced that its subsidiary Kelun Botai’s anti-PD-L1 tagolizumab (trade name: Kotel) was approved for combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). This is the second indication approved for tagolizumab. At the end of December 2024, the China National Medical Products Administration (NMPA) has approved tagolizumab monotherapy for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have failed 2 or more lines of chemotherapy for listing in China. It is worth noting that both among the 20 PD-(L)1 drugs that have been launched in China and in the indication of nasopharyngeal carcinoma, tagolizumab is “late to the party”. As a PD-L1 introduced from Kangfang Bio in 2014, why did Kelun Biotech still launch it to the market despite being “late to the ...
- Source: drugdu
- 267
- February 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.